No Data
No Data
No Data
No Data
No Data
OPI, RVNC and AQST Are Among After Hour Movers
Seeking AlphaApr 22 16:53 ET
Maintaining Caution: AN2 Therapeutics Hold Rating Amidst Epetraborole Trial Uncertainties
TipRanksApr 8 03:55 ET
12 Health Care Stocks Moving In Thursday's After-Market Session
GainersOrgenesis (NASDAQ:ORGS) shares increased by 8.5% to $0.63 during Thursday's after-market session. The company's market cap stands at $21.4 million. AN2 Therapeutics (NASDAQ:ANTX) shares increas
BenzingaApr 4 16:31 ET
AN2 Therapeutics Price Target Announced at $6.00/Share by JMP Securities
AN2 Therapeutics Price Target Announced at $6.00/Share by JMP Securities
Dow JonesApr 2 14:16 ET
JMP Securities Upgrades AN2 Therapeutics to Market Outperform From Market Perform
JMP Securities Upgrades AN2 Therapeutics to Market Outperform From Market Perform.
MT NewswiresApr 2 10:17 ET
Buy Rating Affirmed for AN2 Therapeutics Amidst Upcoming Catalysts and Strong Valuation Prospects
TipRanksApr 2 00:35 ET
NVDAvsTSLA : Waiting for the 2/3 results. If they are good, the price goes up to 21, if fail, drop to 2. If succeed and be approved by FDA, they are going to the moon.
WarrenC : you're buying right now?
Super Waves : Are you buying now?
TrytosaveabitOP WarrenC: I plan on starting a position Monday PM yes! As I said in post. I will start scaling in a bit at a time.
TrytosaveabitOP Super Waves: Plan on it Monday PM to start scaling in a bit at a time!
Tarzanman : yes I'm in this waiting for them to restart trials this shud bounce back over 10 atlst
NVDAvsTSLA : I cannot agree. We need good news to trigger it
No Data
No Data